Increasing hypothalamic arcuate nucleus glial peroxidase activity in aging female rats is reduced by an antiestrogen and a gonadotropin-releasing hormone agonist

David Seifer, Lucia Roa-Peña, David L. Keefe, Heping Zhang, Stephanie Goodman, Ervin E. Jones, Frederick Naftolin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Progressive arcuate glial peroxidase activity is associated with reproductive aging of the female rat. We tested the hypothesis that age-related increase of glial peroxidase activity within the arcuate nucleus and posterior periventricular area is due to endogenous estrogen and could be reduced by an antiestrogen, keoxiphene, or a gonadotropin-releasing hormone super agonist, goserelin acetate (Zoladex), or both. At 3 months of age, 4-5-day regularly cycling female rats were divided into four groups. One group served as a baseline 3-month-old control and was killed by perfusion-fixation followed by serial sectioning of the hypothalamus and staining with 3,3′-diaminobenzidine tetrahydrochloride (DAB). Other groups consisted of animals receiving keoxiphene, goserelin acetate depot (Zoladex), or sham implants for 6 months. Two months after removal of the implants, at 11.25 months of age, the animals were killed by perfusion-fixation, and serial hypothalamic sections were stained with DAB. Sections from each of the four groups were examined in a fixed-size standard test area using a computerized image analyzer to assess the surface density of the DAB reaction. Overall, periventricular peroxidase reaction of the 11.25-month keoxiphene group showed a 63.5% increase in surface density of DAB reaction over the 3-month control group (5,834.6 ± 101.0 [μm2versus 3,566.2 ± 173.6 μm2), whereas the 11.25-month Zoladex group showed a 42.4% increase in surface density of DAB reaction over the 3-month control group (5,078.5 ± 114.6 μm2versus 3,566.2 ± 173.6 μm2). This was in sharp contrast to the 11.25 month sham control group, which showed a 94% increase over the 3-month control group (6,926.6 ± 121.3 (μm2versus 3,566.2 ± 173.6 μm2), p <0.0001. The differences in increase of the surface density of DAB in zone of reaction in keoxiphene-treated and Zoladex-treated rats were not equally distributed throughout the periventricular brain: The greatest difference was noted in the anterior arcuate (p

Original languageEnglish (US)
Pages (from-to)83-90
Number of pages8
JournalMenopause
Volume1
Issue number2
StatePublished - 1994
Externally publishedYes

Fingerprint

Goserelin
Arcuate Nucleus of Hypothalamus
Estrogen Receptor Modulators
Gonadotropin-Releasing Hormone
Neuroglia
Peroxidase
Control Groups
Perfusion
Hypothalamus
Estrogens
Staining and Labeling
Brain

Keywords

  • Arcuate nucleus
  • DAB-Keoxiphene
  • Glial peroxidase activity
  • Goserelin

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Seifer, D., Roa-Peña, L., Keefe, D. L., Zhang, H., Goodman, S., Jones, E. E., & Naftolin, F. (1994). Increasing hypothalamic arcuate nucleus glial peroxidase activity in aging female rats is reduced by an antiestrogen and a gonadotropin-releasing hormone agonist. Menopause, 1(2), 83-90.

Increasing hypothalamic arcuate nucleus glial peroxidase activity in aging female rats is reduced by an antiestrogen and a gonadotropin-releasing hormone agonist. / Seifer, David; Roa-Peña, Lucia; Keefe, David L.; Zhang, Heping; Goodman, Stephanie; Jones, Ervin E.; Naftolin, Frederick.

In: Menopause, Vol. 1, No. 2, 1994, p. 83-90.

Research output: Contribution to journalArticle

Seifer, D, Roa-Peña, L, Keefe, DL, Zhang, H, Goodman, S, Jones, EE & Naftolin, F 1994, 'Increasing hypothalamic arcuate nucleus glial peroxidase activity in aging female rats is reduced by an antiestrogen and a gonadotropin-releasing hormone agonist', Menopause, vol. 1, no. 2, pp. 83-90.
Seifer, David ; Roa-Peña, Lucia ; Keefe, David L. ; Zhang, Heping ; Goodman, Stephanie ; Jones, Ervin E. ; Naftolin, Frederick. / Increasing hypothalamic arcuate nucleus glial peroxidase activity in aging female rats is reduced by an antiestrogen and a gonadotropin-releasing hormone agonist. In: Menopause. 1994 ; Vol. 1, No. 2. pp. 83-90.
@article{08e7f32dbe95408790e80b4b948c8c9b,
title = "Increasing hypothalamic arcuate nucleus glial peroxidase activity in aging female rats is reduced by an antiestrogen and a gonadotropin-releasing hormone agonist",
abstract = "Progressive arcuate glial peroxidase activity is associated with reproductive aging of the female rat. We tested the hypothesis that age-related increase of glial peroxidase activity within the arcuate nucleus and posterior periventricular area is due to endogenous estrogen and could be reduced by an antiestrogen, keoxiphene, or a gonadotropin-releasing hormone super agonist, goserelin acetate (Zoladex), or both. At 3 months of age, 4-5-day regularly cycling female rats were divided into four groups. One group served as a baseline 3-month-old control and was killed by perfusion-fixation followed by serial sectioning of the hypothalamus and staining with 3,3′-diaminobenzidine tetrahydrochloride (DAB). Other groups consisted of animals receiving keoxiphene, goserelin acetate depot (Zoladex), or sham implants for 6 months. Two months after removal of the implants, at 11.25 months of age, the animals were killed by perfusion-fixation, and serial hypothalamic sections were stained with DAB. Sections from each of the four groups were examined in a fixed-size standard test area using a computerized image analyzer to assess the surface density of the DAB reaction. Overall, periventricular peroxidase reaction of the 11.25-month keoxiphene group showed a 63.5{\%} increase in surface density of DAB reaction over the 3-month control group (5,834.6 ± 101.0 [μm2versus 3,566.2 ± 173.6 μm2), whereas the 11.25-month Zoladex group showed a 42.4{\%} increase in surface density of DAB reaction over the 3-month control group (5,078.5 ± 114.6 μm2versus 3,566.2 ± 173.6 μm2). This was in sharp contrast to the 11.25 month sham control group, which showed a 94{\%} increase over the 3-month control group (6,926.6 ± 121.3 (μm2versus 3,566.2 ± 173.6 μm2), p <0.0001. The differences in increase of the surface density of DAB in zone of reaction in keoxiphene-treated and Zoladex-treated rats were not equally distributed throughout the periventricular brain: The greatest difference was noted in the anterior arcuate (p",
keywords = "Arcuate nucleus, DAB-Keoxiphene, Glial peroxidase activity, Goserelin",
author = "David Seifer and Lucia Roa-Pe{\~n}a and Keefe, {David L.} and Heping Zhang and Stephanie Goodman and Jones, {Ervin E.} and Frederick Naftolin",
year = "1994",
language = "English (US)",
volume = "1",
pages = "83--90",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Increasing hypothalamic arcuate nucleus glial peroxidase activity in aging female rats is reduced by an antiestrogen and a gonadotropin-releasing hormone agonist

AU - Seifer, David

AU - Roa-Peña, Lucia

AU - Keefe, David L.

AU - Zhang, Heping

AU - Goodman, Stephanie

AU - Jones, Ervin E.

AU - Naftolin, Frederick

PY - 1994

Y1 - 1994

N2 - Progressive arcuate glial peroxidase activity is associated with reproductive aging of the female rat. We tested the hypothesis that age-related increase of glial peroxidase activity within the arcuate nucleus and posterior periventricular area is due to endogenous estrogen and could be reduced by an antiestrogen, keoxiphene, or a gonadotropin-releasing hormone super agonist, goserelin acetate (Zoladex), or both. At 3 months of age, 4-5-day regularly cycling female rats were divided into four groups. One group served as a baseline 3-month-old control and was killed by perfusion-fixation followed by serial sectioning of the hypothalamus and staining with 3,3′-diaminobenzidine tetrahydrochloride (DAB). Other groups consisted of animals receiving keoxiphene, goserelin acetate depot (Zoladex), or sham implants for 6 months. Two months after removal of the implants, at 11.25 months of age, the animals were killed by perfusion-fixation, and serial hypothalamic sections were stained with DAB. Sections from each of the four groups were examined in a fixed-size standard test area using a computerized image analyzer to assess the surface density of the DAB reaction. Overall, periventricular peroxidase reaction of the 11.25-month keoxiphene group showed a 63.5% increase in surface density of DAB reaction over the 3-month control group (5,834.6 ± 101.0 [μm2versus 3,566.2 ± 173.6 μm2), whereas the 11.25-month Zoladex group showed a 42.4% increase in surface density of DAB reaction over the 3-month control group (5,078.5 ± 114.6 μm2versus 3,566.2 ± 173.6 μm2). This was in sharp contrast to the 11.25 month sham control group, which showed a 94% increase over the 3-month control group (6,926.6 ± 121.3 (μm2versus 3,566.2 ± 173.6 μm2), p <0.0001. The differences in increase of the surface density of DAB in zone of reaction in keoxiphene-treated and Zoladex-treated rats were not equally distributed throughout the periventricular brain: The greatest difference was noted in the anterior arcuate (p

AB - Progressive arcuate glial peroxidase activity is associated with reproductive aging of the female rat. We tested the hypothesis that age-related increase of glial peroxidase activity within the arcuate nucleus and posterior periventricular area is due to endogenous estrogen and could be reduced by an antiestrogen, keoxiphene, or a gonadotropin-releasing hormone super agonist, goserelin acetate (Zoladex), or both. At 3 months of age, 4-5-day regularly cycling female rats were divided into four groups. One group served as a baseline 3-month-old control and was killed by perfusion-fixation followed by serial sectioning of the hypothalamus and staining with 3,3′-diaminobenzidine tetrahydrochloride (DAB). Other groups consisted of animals receiving keoxiphene, goserelin acetate depot (Zoladex), or sham implants for 6 months. Two months after removal of the implants, at 11.25 months of age, the animals were killed by perfusion-fixation, and serial hypothalamic sections were stained with DAB. Sections from each of the four groups were examined in a fixed-size standard test area using a computerized image analyzer to assess the surface density of the DAB reaction. Overall, periventricular peroxidase reaction of the 11.25-month keoxiphene group showed a 63.5% increase in surface density of DAB reaction over the 3-month control group (5,834.6 ± 101.0 [μm2versus 3,566.2 ± 173.6 μm2), whereas the 11.25-month Zoladex group showed a 42.4% increase in surface density of DAB reaction over the 3-month control group (5,078.5 ± 114.6 μm2versus 3,566.2 ± 173.6 μm2). This was in sharp contrast to the 11.25 month sham control group, which showed a 94% increase over the 3-month control group (6,926.6 ± 121.3 (μm2versus 3,566.2 ± 173.6 μm2), p <0.0001. The differences in increase of the surface density of DAB in zone of reaction in keoxiphene-treated and Zoladex-treated rats were not equally distributed throughout the periventricular brain: The greatest difference was noted in the anterior arcuate (p

KW - Arcuate nucleus

KW - DAB-Keoxiphene

KW - Glial peroxidase activity

KW - Goserelin

UR - http://www.scopus.com/inward/record.url?scp=0007785191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0007785191&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 83

EP - 90

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 2

ER -